

Feature Review

Advancing human disease research with fish evolutionary mutant models

Emily A. Beck ^{1,2,*} Hope M. Healey ² Clayton M. Small ^{1,2} Mark C. Currey ²
Thomas Desvignes ³ William A. Cresko ^{1,2} and John H. Postlethwait ³

Model organism research is essential to understand disease mechanisms. However, laboratory-induced genetic models can lack genetic variation and often fail to mimic the spectrum of disease severity. Evolutionary mutant models (EMMs) are species with evolved phenotypes that mimic human disease. EMMs complement traditional laboratory models by providing unique avenues to study gene-by-environment interactions, modular mutations in noncoding regions, and their evolved compensations. EMMs have improved our understanding of complex diseases, including cancer, diabetes, and aging, and illuminated mechanisms in many organs. Rapid advancements of sequencing and genome-editing technologies have catapulted the utility of EMMs, particularly in fish. Fish are the most diverse group of vertebrates, exhibiting a kaleidoscope of specialized phenotypes, many that would be pathogenic in humans but are adaptive in the species' specialized habitat. Importantly, evolved compensations can suggest avenues for novel disease therapies. This review summarizes current research using fish EMMs to advance our understanding of human disease.

Evolutionary mutant models (EMMs) in precision medicine

Humans differ in the probability of developing disease, the severity of disease phenotypes, and in their responses to disease prevention efforts and treatments, in part due to standing genetic variation among individuals [1–3]. Understanding the influence of each individual's genetics on disease etiology led to advances in the field of 'precision' medicine through the development of therapies tailored to genotypes [4]. Research on human patients is critical for revealing connections between genetic variation and differences in health outcomes but is difficult to perform, often involves isolated material such as cell lines rather than intact organisms, and uses genome-wide association studies (GWAS), in which variation is often limited to specific populations.

Model organism research facilitates diagnosis, mechanistic understanding, and searches for therapies for human diseases and relies on forward and reverse genetic screens [5,6]. Forward genetic screens identify desired phenotypes in a randomly mutagenized population, followed by characterizing the mutant genotype. Traditionally, this is accomplished using laboratory models such as worms, flies, zebrafish, and medaka and provides enormously successful models to identify genetic variants underlying an observed phenotype [7]. Human medical genetics is fundamentally a forward genetic screen where the patient displays a phenotype that geneticists link to a specific mutated human gene. Forward genetic screens in model organisms, however, often identify only variants exhibiting extreme phenotypes arising from single gene defects. In contrast, many human diseases, especially chronic pathologies, are rarely caused by full loss-of-function alleles, are often polygenic, occur in our highly outbred population, and can involve altered regulatory regions. Conversely, reverse genetic experiments generate desired genotypes by targeted mutagenesis, made possible with the advent of recombinant DNA, followed by

Highlights

Some animals evolved natural phenotypes that mimic human diseases but are not pathogenic in the animals' specific environments.

Understanding molecular genetic strategies that evolutionary mutant medical models use to compensate for their pathology-mimicking phenotypes can suggest new avenues for novel therapies.

Understanding evolutionary mutant models illuminates the role of genetic variation in disease etiology.

Technical advances in genomics and molecular biology facilitate the expansion of disease research to non-model organisms.

The deep radiation of fish generated a kaleidoscope of specialized phenotypes that mechanistically mimic human disease.

Here we describe seven fish EMMs used to tackle research on nine groups of human diseases.

¹Data Science, University of Oregon, Eugene, OR 97403, USA

²Institute of Ecology and Evolution, University of Oregon, Eugene, OR 97403, USA

³Institute of Neuroscience, University of Oregon, Eugene, OR 97403, USA

*Correspondence: beck8@uoregon.edu (E.A. Beck).



identification of the mutant phenotype [5,8]. Nevertheless, reverse genetics still struggles with phenotypes caused by multiple loci, involve pleiotropy, or appear only with age.

An important addition to forward genetics and reverse genetics comes from evolutionary genetics: EMMs are animals with evolved phenotypes that mimic maladaptive human diseases. Evolutionary genetic screens take advantage of natural phenotypic traits and provide an alternative for discovering underlying genetic variants without the need for laboratory mutagenesis. Instead, EMMs arise when natural selection or **genetic drift** (see [Glossary](#)) shifts the frequencies of alleles underlying phenotypes within populations. While such phenotypes mimic diseases in humans, these traits may be adapted to the particular environment the EMMs inhabit [9]. In some cases, changes involve variants in **orthologs** of known disease genes and result in phenotypes directly mimicking human diseases. These genetic variants and subsequent EMMs arise gradually through similar natural processes as human disease variants and not from chemical mutagenesis, as in forward genetics, or recombinant DNA technology, as in reverse genetics. Furthermore, EMM organisms can be amenable to reverse genetics, such as CRISPR-Cas9 genome editing. The utility

Box 1. Evolutionary mutant model strategy

Evolutionary mutant models (EMMs) of human disease show evolved phenotypes that mimic human disease but nevertheless suit the species in its environment. For example, anadromous stickleback fish have heavy bony plates in their skin. Thousands of times in Asia, North America, and Europe, anadromous stickleback became landlocked in freshwater lakes. Over occasionally remarkably short periods of time, freshwater stickleback evolved into forms with greatly reduced ectodermal plates ([Figure 1A](#)) [10,11]. Some human diseases, like ectodermal dysplasia, also disrupt ectodermal modifications, including small nails, hair loss, reduced sweat glands, and missing teeth ([Figure 1B](#), photo credit bottom: National Foundation for Ectodermal Dysplasias).

Understanding evolved molecular genetic mechanisms that cause a disease-like phenotype to develop in the EMM can lead to novel insights into the etiologies of human disease. In the case of stickleback plates, crosses of anadromous individuals to freshwater morphs led to the mapping of this feature to the stickleback *ectodysplasin* gene [12,13]. Likewise, mutations in the human *ectodysplasin* gene give rise to ectodermal dysplasia disease in people, including reduced and malformed nails ([Figure 1B](#)) [14]. Investigating the molecular genetic mechanisms that integrate the EMM's disease-like phenotype into a functioning whole might provide insights into managing human disease.




Figure 1. The strategy of evolutionary mutant models of human disease. A. A model organism exhibits an evolutionary genetic change: here, the loss of skin modifications (armored plates) from ancestral populations of marine threespine stickleback (top) as the species adapts over generations to freshwater habitats (bottom). B. The evolved model mimics human disease: here, a change in skin modifications, including fingernails (top), to abnormally formed and weak nails in the genetic disease ectodermal dysplasia (bottom). Both phenotypes involve genetic variants of the *ectodysplasin* gene. Mechanistic investigations of the model can inform understanding of the human disease.

Glossary

Admixture: the presence of DNA from individuals of distantly related, formerly genetically isolated populations, resulting from interbreeding.

Conserved noncoding element (CNE): a noncoding genomic region identified by sequence conservation among multiple species.

Epistatic variation: genetic polymorphisms that interact to produce joint, non-additive effects on phenotypes.

Expression QTL (eQTL): genomic loci that are correlated with variation of expression levels of transcripts.

Genetic drift: changes in the relative frequency of alleles in a population due to chance.

Linkage disequilibrium: nonrandom association of alleles from different loci.

Ohnolog: gene duplicates created by a whole-genome duplication event.

Ortholog: genes in different species that evolved from a single gene in the last common ancestor.

Quantitative trait locus (QTL): genomic loci that correlate with an observed quantitative trait.

Syngnathid: a family of teleost fishes, including seahorses, pipefishes, and seadragons, characterized by an elongated snout and male pregnancy.

Teleost: ray-finned fish that have a dorso-ventrally symmetrical tail fin, in contrast to basally diverging ray-finned fish like their sister group, the Holostei (bowfins and garfish), and more basally diverging fish, like Chondrostei (sturgeons and redfish), that have asymmetrical tail fins.

of EMMs for forward and reverse genetics make them ideal bridges between human and laboratory animal model research (Box 1).

EMMs can model the spectrum of genetic complexity in human disease

The spectrum of human disease phenotypes is based on genetic complexity and environmental interactions. Some human diseases, like cystic fibrosis [15], are genetically simple, resulting from mutation(s) in a single gene, and are well suited for study in classical reverse genetic models. More commonly, however, a disease can occur due to mutations in and of several different genes (e.g., Fanconi anemia [16]) or when variants in several genes aberrantly interact (e.g., in Alzheimer's disease [17]). Sometimes, different phenotypes can arise from different alleles of the same gene [complete loss-of-function alleles (amorphs), gain-of-function alleles (neomorphs), or over- or underexpression alleles (hypermorphs or hypomorphs, respectively)] [18,19]. Additional nuanced genetic changes, including suboptimal gene interactions or incompatibility between a mutant gene product and other substances (e.g., proteins, RNAs, or metabolites) can cause a spectrum of disease phenotypes emerging from variants at one or more loci with altered, but not entirely null, function [20–23]. In addition, some pathogenic phenotypes may only appear when certain genotypes experience special environmental conditions, such as variations in regulatory elements gradually diminishing the expression of lactase in adults, resulting in lactose intolerance [24]. EMMs provide a wide range of genetic models, from genetically simple diseases with low environmental influence, to polygenic diseases with high environmental influence [9].

EMMs can identify background-specific disease variants

Studying diseases in a small number of genetic backgrounds is problematic because disease-related genetic variants may only become apparent on a specific genetic background. In humans, **epistatic variation** can lead to ranges of disease severity in different populations. For example, variants of alpha- and beta-globins, including variation upregulating gamma-globin, interact in complex ways influencing the severity of malaria in a population-dependent manner across sub-Saharan Africa [25]. Additionally, environmental conditions impact some genetic backgrounds more than others, in gene-by-environment (GxE) interactions. For example, diabetes in Pima people living in Arizona is higher than in non-Native American populations and is much higher than genetically related Pima people living in Mexico (38% versus 7%) [26].

EMMs harbor genetic variation absent in inbred laboratory models and can be used in manipulative, controlled studies to understand GxE interactions. Specifically, EMMs can help identify population-specific disease variants by studying genetically diverse populations in a common environment and are amenable to powerful techniques to identify population-specific variants such as **quantitative trait locus (QTL)** mapping or GWAS [27,28]. Chances of encountering reduced **linkage disequilibrium**, increased recombination rates, and often quite advanced backcrosses in natural populations increase the power and resolution of these techniques to detect relevant loci underlying phenotypes [28]. These techniques are commonly used to study disease resistance by crossing resistant and nonresistant individuals and comparing the genetics and resistance levels of offspring [29]. Also, because natural populations can be locally adapted to differing environments, new avenues for studying the impact of the environment and genetic background on phenotypic variation can be explored under natural conditions by crossing individuals adapted to different areas either in a laboratory setting or in naturally existing hybrid zones where individuals from different environments interbreed [30].

EMMs can model noncoding genetic variants

The study of noncoding genetic variants is essential to understand complex human diseases because 88% of loci linked to diseases in GWAS are in noncoding regions [31]. Human disease

research, however, focuses mostly on coding regions even when associated variants are identified in noncoding regions. For example, multiple GWAS identified the first intron of the dioxygenase gene *FTO* to be associated with obesity, leading to extensive study of *FTO* in obesity research [32]. No direct links, however, were found between *FTO* expression and obesity. Instead, a long-range enhancer in this region that regulates *IRX3* several megabases away was identified, which has direct links to obesity [32].

Some conserved regulatory functions lie in **conserved noncoding elements (CNEs)** that become apparent in whole-genome alignments performed across multiple species [33]. Comparing genetically diverse species with phenotypic characters of interest can reveal CNEs with specific trait associations. These types of associations have been used to identify CNEs altered in human diseases, such as the disruption of an *IRF6* enhancer binding site in cleft lip and palate [34] and a mutation in a *RET* enhancer in Hirschsprung disease [35].

Due to a high level of sequence and synteny conservation within mammals, DNA sequence alignments with fishes are particularly valuable for identifying and assigning CNEs to their target gene [36]. Missing or highly derived CNEs in EMMs may indicate regulatory elements involved in the development of their unique features; therefore, these CNEs are candidate targets to explore the diseases they model. For example, **syngnathid** fishes are potential models for craniofacial disorders (they are toothless and possess uniquely shaped craniofacial bones adapted to allow for rapid suction feeding) [37]. Researchers identified a deeply conserved CNE in an intron of *dlx1a* that was lost in the Gulf pipefish, a syngnathid [38]. Based on the role of *dlx1* in craniofacial development, this CNE is a potential target to explore in the context of human disease [39].

Variants of CNE or other regulatory mutations can also be identified in EMMs by crossing EMMs from different populations and comparing gene expression patterns to phenotypes via **expression QTL (eQTL)** mapping or phylomapping (Box 2) [27]. Noncoding mutations can also cause nuanced changes in gene expression that may contribute to the spectrum of disease severity [9]. For example, people with hypodontia develop many fewer than the normal number of teeth and those with hyperdontia develop many more teeth than normal [40]. Stickleback fish model these conditions. Benthic freshwater stickleback populations have twice as many pharyngeal teeth as marine populations [41]. Crosses of hypodontic by hyperdontic stickleback and gene expression analyses showed that responsible changes were in regulatory elements for *bmp6* (bone morphogenetic protein-6), leading to increased *bmp6* expression in the population with more teeth [41,42].


The utility of fish EMMs

EMMs for human diseases exist in a diverse array of animal groups, including anoles as models for congenital heart disease [45] and giraffes and pikas as models for hypertension [46,47]. Recently, EMMs with superior antiviral defenses, including pangolins, bats, and naked mole rats, have proven particularly useful in the study of highly transmissible viruses like severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [48]. EMMs, however, are especially prevalent in fishes for a variety of reasons. The clade of ray-finned fishes (Actinopterygii), to which the models in this review belong, contains roughly half of all extant vertebrate species [49–54]. The ancient origin of this clade, in combination with the often-large population sizes and extensive geographic ranges of species in this group has likely contributed to the clade being very speciose. Phenotypic diversity arises from the wide range of habitats in which fish have evolved. Adaptations to extreme temperatures, salinities, light levels, water pressures, and primary producer abundances resulted in wide-ranging phenotypes. Genome duplication events, which are numerous among actinopterygian lineages [50–53,55–58], also likely provided a substrate for diversification by increasing gene numbers and relaxing molecular evolutionary constraints [53,55]. Gene duplicates

Box 2. Phylomapping for fish evolutionary mutant models

Phylomapping is an important methodology to identify candidate loci that underlie naturally occurring phenotypes mimicking human disease [43]. Phylomapping involves a clade with an outgroup (o) and inferred phylogenetic relationships to orient evolutionary change (Figure 1A). The clade contains multiple lineages that independently evolved disease-like phenotypes, for example, skeletal development that mimics dwarfism (Figure 1B, species 2 and 4). Comparing genome sequences within the clade compared with the outgroup can identify: (1) variants derived and shared by the queried clade, (2) variants unique to various subclades, (3) variants private to each species, and (4) lesioned genes or regulatory motifs that are shared only by lineages showing the disease-like phenotype (Figure 1C). If the shared, lesioned, phenotype-associated genes have the same genomic changes in different species showing the phenotype, then they might be derived by lineage sorting from standing genetic variation, as has occurred in stickleback [10,12,44]. Alternatively, lesioned genes shared by independently derived evolutionary mutant model phenotypes might have different molecular genetic changes in the same genes, indicating independently derived mutations leading to similar phenotypes.

Mutated candidate genes in laboratory models, like zebrafish or medaka, that result in phenotypes similar to the EMM, support the hypothesis that the candidate gene causes the observed 'pathogenic' phenotype. This approach led to the identification of fibroblast growth factor receptor variants as candidates for the reduction of bony scales in fishes of the genus *Phoxinellus* [43]. Future phylomapping studies of phenotypes that vary within a specific clade, such as longevity, pigment, craniofacial features, behavioral traits, and many other characters, promise to identify not only protein-coding genes, but also potential regulatory elements and noncoding genes associated with the evolution of disease-like traits.



Trends in Genetics

Figure 1. The rationale of phylomapping. A–B. Phylogenetic relationships of a clade in which some lineages evolved a disease-like trait: dwarfism in species 2 and 4. C. Genomic sequencing in the clade and an outgroup (species 0) will reveal nucleotide polymorphisms in or near genes that are: 1) derived within the whole clade compared to the outgroup; 2) specific to certain sub-clades within the larger group regardless of the phenotype; 3) private to individual species; or 4) possessed only by species displaying the disease-like trait, thus identifying candidate genes or variants for causative factors. Mechanistic studies can test the role of the candidate gene in the evolved phenotype.

have greatly expanded avenues for evolution providing multiple copies of genes that can evolve new functions (neofunctionalization) or partition pre-existing functions (subfunctionalization) [56,57]. In some cases, these duplicates contribute to highly derived morphologies and unique adaptations that can be used to study orthologous disease phenotypes in humans. Advances in molecular and genomic tools have greatly expanded EMM utility; many of these organisms

now have high-quality reference genome sequences and can be manipulated using laboratory techniques such as CRISPR-Cas9 genome editing. Later, we describe seven fish EMMs used to tackle research on nine groups of human diseases (Box 3; Table 1; Figures 1 and 2).

Box 3. Validating evolutionary mutant models for human disease

From November 2020 to January 2021, the National Institutes of Health (ORIP, NHLBI, NIA, NIDDK, NIGMS, NINDS) held a workshop entitled: *Validation of Animal Models and Tools for Biomedical Research*⁴. Principles from those workshops apply to models of human disease in general and include three types of validation.

Face validity. Does the model replicate human disease clinical findings? Are the pathological phenotypes similar? Do they involve corresponding organs and cell types? Face validity can be achieved in fish EMMs because fish and humans share vertebrate organs and organ systems.

Construct validity. Does the model reflect the mechanisms of the human disease? The model should involve orthologous genes with similar gene expression patterns, utilize similarly acting noncoding elements, and display comparable epigenetic marks; the model's proteins should share intracellular locations with the corresponding human protein; and the model should react to pharmacological agents as people do. Genomic studies showed that fish have orthologs of at least 82% of human genes with morbidity descriptions [59].

Predictive validity. Can the EMM foretell currently unknown aspects of human disease? The true value of EMMs is that they can lead to a deeper understanding of disease mechanisms and thus to previously unknown disease features researchers can verify in human patients, potentially leading to novel disease therapies.

A case study: EMM validation and hybrid *Xiphophorus* malignant melanoma (MM)

Melanoma is one of the deadliest forms of cancer, with postdiagnosis survival averaging only about a year [60,61]. The earliest fish EMM, a small Mexican fish in the genus *Xiphophorus* described in 1927, has provided a number of important insights into MM [62–65]. The southern platyfish (*X. maculatus*) has a dark pigment spot on the dorsal fin but the green swordtail (*X. helleri*) lacks this pigmentation state (Figure 1A; photo credit Manfred Schartl). A quarter of hybrid backcrossed individuals of these *Xiphophorus* species develop MM; a quarter show hyperpigmentation; and half are normal [64,66–68], as expected from Mendelian segregation of two unlinked epistatic loci (Figure 1B,C; photo credit Manfred Schartl).

Xiphophorus MM shows face validity because it replicates clinical findings in human MM. Fish have melanocytes in their epidermis, like humans, whereas mice have melanocytes in hair bulbs but not their skin [69]. Furthermore, *Xiphophorus* MM proceeds from pigmented nevi through radial growth, then into a vertical invasive growth phase, as do human melanomas.

Xiphophorus MM shows construct validity by reflecting the mechanisms of human MM. The platyfish melanoma driver oncogene is a constitutively activated EGF-receptor (EGFR) homolog called *xmrk* [66]. This discovery reflects the importance of the mutation of *EGFR* in human melanoma, malignant glioma, lung cancers, and more. In addition, the transcriptional disease signature of *Xiphophorus* MM matches human melanoma transcriptomes [70] suggesting that orthologous genes and pathways lead to the same pathologies by the same genetic and cellular mechanisms in fish and humans. Additionally, drugs that are effective in fighting human melanoma, like trametinib and cisplatin, also act on *Xiphophorus* MM [70], confirming shared pathogenic mechanisms of MM in fish and humans.

Xiphophorus MM has predictive validity because results from *Xiphophorus* studies forecast findings shown later for human MM. *Xiphophorus* MM genetics first introduced the concept of tumor promotor genes (now called oncogenes) and tumor suppressor genes [71]. *Xiphophorus* results predicted that the RTK/RAS/RAF/MAPK pathway is the critical driver for human melanoma a decade before it was detected in humans [72]. *Xiphophorus* studies predicted a mechanism of interferon resistance in first-line melanoma treatments [73]. Osteopontin was first identified in *Xiphophorus* MM as a key factor in the transition from radial to vertical growth and this finding led to its use in diagnostics and as a prognostic marker in the clinic [73–75]. Recent results showed that *rab3d* is the *Xiphophorus* tumor suppressor gene [76]. Human RAB3D is involved in exocytosis [77] and its elevated expression promotes cancer progression and metastasis [78], but its role in MM in humans has not yet been shown. Studies of *rab3d* mechanisms in *Xiphophorus* may suggest new avenues for developing therapies for human melanomas.

Molecular identification of the *xmrk*; *rab3d* pair in *Xiphophorus* is particularly promising for studying novel melanoma therapies because small aquarium fish enable high-throughput screens for drug-like molecules with potential therapeutic use [79]. The demonstration that the *Xiphophorus* model for human MM meets criteria for face, construct, and predictive validation verifies its use as an important EMM for human disease.





Figure 1. *Xiphophorus* malignant melanoma. A cross between a male swordtail (*X. helleri*) to a platyfish female (*X. maculatus*) (A) produces hybrid offspring (B) that are heterozygous for partially dominant alleles of an oncogene (*On*) and a tumor suppressor gene (*Ts*). A backcross of hybrids to swordtails produces four types of offspring (C): those that have the tumor-causing allele of the oncogene but lack the suppressor allele and develop melanomas; those with one copy each of the oncogene disease allele and the platyfish allele of the tumor suppressor gene, which are merely hyperpigmented; and phenotypically healthy fish that lack the disease allele of the oncogene.

African turquoise killifish, a model of aging

Aging is the primary risk factor for many pathologies, with age-related diseases affecting most aspects of human health. Unfortunately, modeling age-related diseases, particularly in vertebrates, is difficult due to long lifespans [80]. While invertebrate models of aging, including flies and nematodes, have been useful in studying highly conserved age-related genetic pathways, invertebrates lack (or have ancestral versions of) many critical human organ systems (e.g., cartilage and bone, spleen, gall bladder) and cannot be used to study the effects of aging in those organs relevant to age-related diseases [81]. Organisms with exceptionally long lifespans are used to study aging pathways and age-related diseases [82–84], but genetic analysis of aging can also be performed in an expedited fashion using short-lived species. Importantly, using phylomapping

Table 1. Summary of fish evolutionary mutant models and their benefits as medical models

Common name(s)	Scientific name(s)	Disease	Breed in captivity	Genome sequence available	Refs
Swordtail Platyfish	<i>Xiphophorus helleri</i> <i>Xiphophorus maculatus</i>	Melanoma	Y	Y	[68]
African turquoise killifish	<i>Nothobranchius furzeri</i>	Aging	Y	Y	[85]
Notothenioid	Notothenioidei	Skeletal dysplasia	Y/N	Y	[113]
Antarctic icefish	Notothenioidei: Channichthyidae	Anemias	N	Y	[114]
Electric fish	Mormyridae and Gymnotiformes	Channelopathies	Y	Y	[134,199]
Mexican cavefish	<i>Astyanax mexicanus</i>	Cardiac regeneration Metabolic disease	Y	Y	[200]
Mummichog	<i>F. h. heteroclitis</i> <i>F. h. macrolepidotus</i>	Mitochondrial disease	Y	Y	[201]
Threespine stickleback	<i>Gasterosteus aculeatus</i>	Inflammatory bowel disease	Y	Y	[202]



Trends in Genetics

Figure 1. Summary of fish evolutionary mutant models and affected organ systems. Each circle includes a line drawing of a ray-finned evolutionary mutant model with common name and the diseased organ system primarily modeled in that species. (Mexican cavefish/heart and pancreas; Antarctic icefish/bones and blood; turquoise killifish/whole body; platyfish and swordtail/skin; electric fish/whole body; threespine stickleback/intestines; mummichog/brain). Lines connect these groups to their human counterparts.

or other genome-wide comparisons between short- and long-lived species could help identify relevant genetic changes in age-related pathways (Box 2).

The African turquoise killifish *Nothobranchius furzeri* is a unique short-lived model for aging because it has the shortest lifespan (4–9 months) of any vertebrate that can be kept in captivity [85,86], shares vertebrate organs and genes with humans, and exhibits typical age-dependent pathologies (e.g., cognitive decline, loss of fertility, and cancer) [81]. Their telomere length is also more similar to that in humans than mammalian models such as mice [81], making them




Figure 2. Evolutionary relationships of fish EMMs discussed in this review. Phylogenetic relationships among the fish evolutionary mutant models (EMMs) discussed in this review (in blue), in addition to the traditional model zebrafish (*Danio rerio*) and the non-teleost outgroup spotted gar (*Lepisosteus oculatus*). These relationships, published by Rabosky *et al.* [203] are time-calibrated, with branch lengths in units of millions of years (MY) and scaled according to the bar below the tree. Also noted is the timing of the teleost genome duplication (TGD) event.

useful to study mechanisms of aging. While similar telomere size is observed in other fish species, including zebrafish (*Danio rerio*), studies of genetically manipulated African turquoise killifish can be more rapidly studied due to their shortened lifespan and early onset of age-related pathologies, including telomere shortening, making them useful to tackle high-throughput screening of age-related genes. Importantly, variation of lifespan varies across populations, providing unique avenues for comparative genomics between populations to identify genetic changes associated with changes in lifespan [87].

The recent assembly and analysis of the African turquoise killifish genome helped elucidate the complex genetics of aging [85]. Molecular clock studies identified 497 genes evolving adaptively, 22 of which were previously associated with roles in truncated lifespan in mouse and human [85]. Some of these genes were known human disease genes. Specifically, *rte1* showed evidence of adaptive evolution in African turquoise killifish and functions as a helicase involved in telomere elongation [85]. In humans, loss of *RTEL1* function is tied to dyskeratosis congenita, a disease characterized by shortened telomeres and premature aging [88]. The same molecular clock study also revealed adaptive evolution in *Imna(3of3)* [85]; mutations of the human ortholog can cause Hutchinson-Gilford progeria syndrome associated with decreased longevity [89]. Rapid evolution of these aging-related genes in African turquoise killifish provides evidence of conserved genetic mechanisms of aging and illustrates the value of studying aging in this system. In 12 other cases, comparisons with exceptionally long-lived species, including the naked mole rat, Brandt's bat, and the bowhead whale, revealed similar signals of positive selection although on different residues, including positive selection on the insulin/IGF signaling gene *igf1r* in Brandt's bat and the marmoset, the shortest-lived primate [85]. Interestingly, this study also identified genes that may play roles in aging but have not yet been linked to age-related diseases in other animal models or humans and included gene ontology enrichment of genes involved in signal

transduction pathways, metabolism, development, proteostasis, and immunity [85]. Future functional analysis of these genes is needed to discern their roles in aging.

African turquoise killifish provides an example of how study of EMMs can lead to novel disease therapies [90]. In humans and in African turquoise killifish, aging is associated with a decrease in the number of species in the gut microbiome. This finding raised the possibility of a novel treatment, microbiome transfer, to slow the process of aging [90]. The transfer of the gut microbiome of young fish to middle-aged fish resulted in increased longevity of the recipient [90]. Importantly, weeks after transfer, the diversity of the recipient microbiota in the recipient was much greater than in the control group, meaning the recipient's microbiome continued to resemble that of a younger fish. RNA-seq on host tissue also demonstrated microbial transfer impacts on gene expression of pathways typically associated with younger fish, including proliferation as well as ribosomal genes *rps* and *rpl* associated with aging [90]. These experiments suggest the African turquoise killifish could provide insight into alternative mechanisms to slow the process of aging and suggest new therapies for aging via diet, fecal transfer, probiotics, or whole microbiome transfer.

Notothenioids, models of skeletal dysplasias

Skeletal dysplasias are a heritable group of more than 450 disorders that primarily affect bone and cartilage formation and occur in approximately one in 5000 births [91]. Among skeletal dysplasias, osteogenesis imperfecta (OI, 'brittle bone disease') presents at birth and results in bones that can break easily, often from little or no apparent trauma. The severity of this disorder varies among affected people and ranges from mild cases, increasing the risk of bone fractures, to severe forms causing death before or shortly after birth [92,93].

Notothenioids (Notothenioidei) have unique adaptations, making them an excellent model to explore the genetic bases of skeletal dysplasias and OI. Notothenioids are endemic to Antarctic and sub-Antarctic waters and derived from a common ancestor confined to the sea floor due to a highly mineralized skeleton and the absence of a swim bladder, the organ that allows fish to achieve neutral buoyancy. As species diversified, some lineages independently colonized the food-rich water column left vacant by species unable to survive the freezing waters of Antarctica [94]. The transition into the water column was accompanied by increased buoyancy, which in most cases resulted from reducing 'heavy' body parts, like bones, and accruing 'lighter' substances, such as lipids [95,96].

Notothenioids had previously been proposed as a model for osteopenia and osteoporosis [9,97]; however, the developmental and morphological characteristics of the notothenioid skeleton do not solidly align with the progressive, degenerative nature of osteoporosis. Indeed, morphological and molecular skeletal analyses of notothenioids revealed developmental heterochronies (alteration in the timing and rates of bone development), generally reflecting pedomorphic characters. The most buoyant notothenioids show delayed mineralization of bony elements, slow rates of osteological development, smaller bones with persistent cartilage between bone veneers, or even bone loss (Figure 3) [98–100]. Thus, notothenioids do not lose bone as they age, but instead never form well-developed bones, hinting at developmental alterations similar to human skeletal dysplasias, including OI. Supporting this hypothesis, a recent phylogenomic study found that the genes *col1a1a* and *col1a2*, the human orthologs of which account for up to 90% of OI cases in human [92,93], experienced positive selection in the evolutionary branch, leading to the subgroup of notothenioids with reduced skeletons [101]. Furthermore, *col1a* gene mutations in zebrafish show phenotypes that mimic human OI [102], and during larval development of notothenioids, the chondrogenic genetic program, revealed by *col2a1* expression, persists,




Figure 3. Notothenioids, models of skeletal dysplasias. Morphological and molecular analyses of notothenioids revealed alterations in the timing and rates of bone development in several lineages. Compared with bottom dwellers (e.g., humphead notothen), more buoyant notothenioids (e.g., ocellated icefish) show delayed mineralization of bony elements, slow rates of osteological development, smaller bones, or even bone loss as seen in computed tomography scans of craniofacial regions of juveniles of comparable sizes.

while an osteogenic program, revealed by *col1a1* expression, is delayed and reduced [103]. In addition, genes such as *sparc* and *notch2*, associated with OI Type XVII [93] and Hajdu Cheney syndrome, respectively, which display phenotypic features overlapping OI [92,104], are both required for craniofacial skeleton development in zebrafish [105,106] and both genes also experienced positive selection in the ancestor of notothenioids displaying skeletal reduction [101].

While previous genetic studies on notothenioid skeletal evolution queried only genes already known to be associated with bone development, future research should explore the role of candidate genes with as yet unknown roles in skeletogenesis to illuminate ways by which notothenioids evolved an adaptive reduced skeleton and potentially identify novel regulators of bone formation and maintenance in human. Furthermore, different lineages of notothenioids show varying degrees of skeletal reduction and different combinations of gene variants, thus displaying the potential to associate specific genetic variants with phenotypic variations, as seen in human patients.

Antarctic icefishes, models of anemias

Anemias affect the abundance and morphology of red blood cells or the function of hemoglobin, which can result in decreased capacity to deliver oxygen to tissues and to return carbon dioxide for elimination. Anemias affect up to 27% of the world's population, mostly in developing countries, with young children and women of reproductive age being particularly affected [107]. The 16 species of white-blooded Antarctic icefishes (Notothenioidei, Channichthyidae) are unique among vertebrates because they lack functional hemoglobin genes and, in six species, also fail to express cardiac myoglobin [108]. Icefish blood, therefore, is opalescent white and transports only about 10% as much oxygen as blood in a red-blooded relative, making them particularly sensitive to hypoxia [109] (Figure 4). Antarctic icefishes also do not form mature erythrocytes, with the most advanced erythropoietic cells displaying abnormal morphologies and fragility [110–112].




Figure 4. Antarctic icefishes, models of anemias. Compared with their red-blooded relative [e.g., (A) bullhead notothen], the 16 species of white-blooded icefishes lack functional hemoglobin genes [e.g., (B) South Georgia icefish] and, in six species, also fail to express cardiac myoglobin [e.g., (C) blackfin icefish]. Compared with dark-red hearts of red-blooded species (A1), hearts of icefish species expressing myoglobin are pink (B1) and beige in icefish species failing to express myoglobin (C1). The blood of red-blooded species is dark red and contains a large fraction of erythrocytes (A2; left, fresh blood; right, blood after centrifugation) that are ovoid (A3, Wright-Giemsa stain). In comparison icefish blood appears opalescent white and contains only limited amount of blood cells, majorly white blood cells and thrombocytes (B2, C2). A few erythropoietic cells are present in icefish blood, however, they display abnormal morphologies and fragility (B3, C3). Abbreviations: a, atrium; c, blood cells; e, erythrocytes; o, outflow tract; p, plasma; v, ventricle.

This extreme phenotype makes icefishes an excellent model for several human blood disorders, such as anemias, hemoglobinopathies, and thalassemias.

Genomic studies revealed that, of alpha- and beta-globin genes possessed by related red-blooded species, icefishes lost all except a single exon of one alpha-globin gene [113–115]. In addition to studies that aim to understand the genetic mechanisms associated with the loss of hemoglobin and the failure of erythropoiesis in icefishes [116–121], research efforts also focus on the physiological adaptations that enabled Antarctic icefishes to survive and diversify, despite their maladaptive blood condition. Specifically, recent studies revealed evolutionary compensations in the vasculature supplying oxygen to the oxygen-thirsty retina [122,123], in the physiological capacities of hearts lacking hemoglobin and myoglobin [124–126], in the mitochondria [114,127], and in the innovation of a plasma-accessible carbonic anhydrase that catalyzes CO₂ excretion in the gills [128]. These adaptations show that the loss of hemoglobin in icefish is a harmful trait that required compensation. Understanding the genetic mechanisms involved in these physiological compensations and tissue remodeling that permit Antarctic icefishes to survive has the potential to uncover alternative strategies to treat human anemias.

Electric fishes, models of channelopathies

Channelopathies are diseases caused by aberrant function of ion channels that commonly impact the nervous, cardiovascular, respiratory, and immune systems [129]. Generally, channelopathies are caused by mutations that alter channel gating, causing improper fluctuations of ion concentrations. These mutations are tied to many common diseases, including epilepsy, cystic fibrosis, and cardiomyopathy, and are responsible for at least one in five cases of sudden infant death syndrome [129,130]. In electric fishes, electrocytes that compose electric organs contain highly modified ion channels. Ions move synchronously through these channels to produce electric organ discharges. Fine-tuning of channel functions gives rise to a vast diversity of electric signals in these fish [131], performing many roles, including self-defense, navigation, and communication [132].

Mutations that alter channel function (such as altered channel inactivation time) allow electric fish to produce electric signals, but mutations in homologous genes in humans lead to channelopathies [133]. Electric organs in mormyrids (elephantfishes) and most gymnotiforms (knifefishes) are useful for modeling channelopathies afflicting skeletal muscle [134]. In these two fish lineages, the ion channel gene *scn4aa* experienced numerous amino acid substitutions at sites that cause disease phenotypes in the human homologue *SCN4A* [135]. One such mutation alters the inactivation gate that closes the channel leading to membrane hyperexcitability and likely aids in signal production for the electric organ but results in pathological muscle stiffness in humans [135,136]. Mutations induced in *scn4aa* via CRISPR/cas9 in both a mormyrid and gymnotiform resulted in decreased signal amplitude, demonstrating that the electric signal is modulated by changes in ion channel sequence, providing a novel and quantifiable method for testing genetic modifications on electric signals [137]. Recent work also showed interesting evolutionary histories of the mormyrid voltage-gated potassium ion channel gene *kcn7a*. In humans, *KCNA7* has been linked with two human cardiac disorders via mapping studies: progressive familial heart block type 1 and isolated cardiac conduction, though no causative mutations have been found [138]. The earliest diverging member of the electric fish clade, *Gymnarchus niloticus*, retained a *Kcna7a* protein sequence similar to non-electric sister taxa, while other members of the clade accumulated changes indicating positive selection [139]. These genetic modifications cause differences in channel activation sensitivity by modifying the S3-S4 linker domain [139], a previously underexplored region of this protein. These studies show that electric fish are an excellent system to discover and explore mutations in ion channels that may underlie human channelopathies.

Mexican cavefish, a model of diabetes and metabolic diseases

Metabolic diseases, particularly those related to the regulation of blood glucose, are pervasive threats to the wellness and longevity of hundreds of millions of people worldwide [140]. These concerns are increasing due to modern western diets that are especially high in sugars and fats [141], with obesity and diabetes recently reaching epidemic proportions [142]. Species adapted to extreme dietary conditions should be useful for understanding metabolic diseases such as diabetes mellitus, hepatic steatosis, metabolic syndrome, and obesity.

Cave-dwelling populations of the Mexican tetra *Astyanax mexicanus* repeatedly evolved from ancestral riverine populations [143]. Brief periods of abundant food in caves are followed by long periods of nutritional deficit, so life in caves requires the ability to survive through extended stretches of starvation [143]. Cavefish show frenzied ‘binge eating’ and an adaptive metabolism that favors long-term usage of stored energy reserves [144]. Interestingly, cave-adapted *A. mexicanus* exhibit many traits similar to metabolic disease states in humans [144–146]. For example, cave-dwelling Mexican tetra populations are insulin-resistant [145], a trait commonly observed in type 2 diabetes, but in Mexican tetras this trait provides an advantageous metabolism without the negative effects of diabetes, including inflammation.

Insulin resistance in cavefish is caused by reduced binding of insulin to its receptor due to a point mutation in the receptor. CRISPR-Cas9 genome editing to induce the same single base pair mutation in zebrafish resulted in an observed increase both in body mass and in insulin resistance [145]. Cave-dwelling and surface fish experience similar lifespans and similar advanced glycation end-product (AGE) levels in their blood, making *A. mexicanus* a potentially valuable model for understanding compensatory mechanisms to extreme insulin resistance [145]. Precise knowledge of the mechanisms by which cavefish limit accumulation of AGEs amid extreme blood glucose level fluctuations could ultimately lead to therapeutics. For instance, because excessive AGEs lead to vascular damage and ultimately cardiovascular diseases [147] and retinopathy [148], preventing the accumulation of AGEs could mitigate these severe symptoms of diabetes. Such treatments, perhaps through gene therapy approaches (e.g., mimicking AAV delivery of *FGF21* in diabetic mice [149]), could be revealed by future insights from the genetics of cavefish-derived metabolic pathways.

Mexican cavefish, also a model of cardiac regeneration

Globally, myocardial infarctions or heart attacks, are the most prevalent cause of human mortality. These deadly episodes result in the death of billions of cardiomyocytes and the deposition of a permanent fibrotic scar [150] caused by the inability of heart tissue to heal completely and regenerate. Several fish species are capable of varying degrees of regeneration, including zebrafish, which can regenerate cardiac tissue and have been useful in studying mechanisms of regeneration [150]. Interestingly, while the uniform way in which zebrafish are able to regenerate tissue has been useful in identifying important candidate genes and genetic pathways, comparisons between closely related individuals with differing morphologies is not possible in these species [150]. Instead, Mexican cavefish are being developed as a model for cardiac regeneration not only for their regenerative abilities, but for the population-specific manner in which they regenerate cardiac tissue. Surface-dwelling Mexican cavefish have pronounced differences in heart development, morphology, and ability to regenerate cardiac tissue compared with nearby cave-dwelling conspecifics; the ability to regenerate cardiac tissue provides an emerging system to study mechanisms underlying this potentially life-saving adaptation [151].

Morphologically, Pachón cavefish have smaller ventricles and a lower heart rate than surface-dwellers [152]. Surface-dwellers, however, are capable of cardiac regeneration, while Pachón cavefish form fibrotic scars, as do humans after heart attacks [151]. Because Pachón cavefish and surface fish can interbreed, QTL analyses are feasible and have identified genes associated with cardiac regeneration [150], including three extracellular matrix related genes, *si:dkeyp-69c1.7*, *ncam1a*, and *itgam*, that were not previously associated with heart regeneration [151]. Transcriptomic analysis of heart ventricle tissue of the two morphs revealed numerous genes associated with immune and scarring responses, including *lrrc10*, the human ortholog of which is associated with dilated cardiomyopathy and was upregulated in regenerating hearts of surface fish [151]. Follow-up reverse genetic studies in zebrafish showed that *lrrc10* knockout reduced regeneration, but not cardiomyocyte proliferation, therefore no scar was formed [151]. Important work comparing immunopathological responses between surface- and cave-dwelling cavefish provides a strong hypothesis for the origins of the differences in fibrotic scarring. Researchers identified differences in immune cell composition using single-cell approaches and demonstrated that while surface-dwellers maintain balanced use of the innate and adaptive immune systems, cave-dwellers rely heavily on the adaptive immune system, likely due to long-term adaptation to low parasite load [153]. This result means that cave-dweller immune systems are challenged less frequently, leading to altered robustness of certain immune responses, including more sensitive and prolonged immune response of proinflammatory cytokines [153]. These early experiments demonstrated the strength of *A. mexicanus* as an EMM for cardiac regeneration.

Interbreeding cave and surface fish populations provide a unique opportunity to identify new loci and functionally test candidate genes, including those identified in existing QTL datasets.

Mummichog, a model of mitochondrial diseases

Unsuccessful interactions between mitochondrial and nuclear genomes can result in mitochondrial dysfunctions (mt-dys), which causes mitochondrial diseases [154–156]. Unfortunately, diagnosis of mitochondrial diseases has been historically challenging because many genetic pathways impacting mitochondrial activity remain undescribed. Primary mitochondrial diseases (PMD) are characterized by perturbed oxidative phosphorylation (OXPHOS) due to mutations in an OXPHOS protein or a protein that directly interacts with them. Mutations in either the mitochondrial genome or the nuclear genome can perturb OXPHOS function and causes diseases like Leigh syndrome (mitochondrial-encoded *ATP6*), Barth syndrome (nuclear-encoded *TAZ*), and Pearson syndrome (various mitochondrial gene deletions) [157]. PMDs present a wide range of symptoms but are commonly characterized by neuromuscular degeneration. As studies of mitochondrial activity have increased, however, common disorders previously unassociated with mt-dys have been recharacterized as secondary mitochondrial dysfunctions (SMD), including Alzheimer's disease, Parkinson's disease, muscular dystrophy, and autism spectrum disorder [157]. Study of SMDs is complicated by the strong role of genetic variation in nuclear and mitochondrial genomes and the influence of the environment in mt-dys [157,158].


The mummichog *Fundulus heteroclitus* provides a unique system to understand the roles of mitochondrial and nuclear genetic variation on the progression of mt-dys. This species includes two morphologically distinct and interbreeding subspecies (*Fundulus heteroclitus* and *Fundulus heteroclitus macrolepidotus*) along the east coast of the United States with different mitochondrial haplotypes. These subspecies are largely separated at the Hudson River in New Jersey due to previous glaciation. The northern population, *F. h. macrolepidotus*, lives in conditions up to 12°C colder than the southern *F. h. heteroclitus*. In a hybrid zone between these interbreeding populations, **admixture** of mitotypes and nuclear alleles results in many mito-nuclear combinations that can be used to study the complex polygenic nature of mt-dys in the broader context of environmental and genotypic variations [159–161]. This hybridization population is particularly useful for studying the effects of two common environmental stressors on mt-dys: temperature and oxygen availability, which both influence mitochondrial physiology, with low temperatures and low oxygen both suppressing mitochondrial function and reducing metabolic rates [159,161]. This natural hybrid population of mummichogs has been utilized to study not only classical PMD genetics, but nuclear genetic variants that might not have previously been associated with mt-dys or perhaps only result in mt-dys under certain environmental stressors [159]. More work is needed to fully characterize this system, though its evolutionary history has the potential to provide insight into the complex GxE interactions underlying mt-dys.

Threespine stickleback, a model of inflammatory bowel diseases (IBDs)

IBDs, which include ulcerative colitis and Crohn's disease, affect nearly seven million people worldwide [140] and cause chronic inflammation of the gastrointestinal tract that can lead to debilitating pain, anemia, and an increased risk for colorectal cancer [162,163]. The pathologic chronic inflammation of IBD can be identified using markers of inflammation, including presence of excessive numbers of neutrophil cells. Several interacting factors are associated with IBD, including genetic variation, gut microbiome composition, and diet. Understanding the complex nature of these diseases at mechanistic and systems levels has proven to be a major challenge [164]. Experimentally tractable animal models with high levels of standing genetic variation, like threespine stickleback *Gasterosteus aculeatus*, have the potential to be especially useful for understanding IBD.

Countless natural stickleback populations were founded through repeated colonization of fresh-water habitats by oceanic ancestors over hundreds of thousands of years, resulting in substantial interpopulation differentiation in genotypes and phenotypes [12,165]. Recent experiments showed that the stickleback genotype influences the makeup of its gut microbiome [166,167], with some of the same host genotype-driven bacterial lineages comprising stickleback and mammalian guts [166,168]. Further investigation of oceanic and freshwater populations revealed important inflammation-related differences in the abundance of intestinal neutrophils (Figure 5) [169]. The adaptation of gnotobiotic experimental procedures to stickleback allowed testing of how neutrophil abundance depends on the genetic background of the host in response to a microbial stimulus [169]. Controlled microbial exposure using gnotobiotic animals revealed a more robust microbial stimulation of neutrophil activity, indicating a more robust immune response to resident microbes, in an oceanic population compared with a fresh-water population, thus mimicking humans with IBD [169]. A subsequent study of the same populations showed an especially large effect of genetic background on gene expression in the gut, with subtle indications of microbial and ‘host genotype-by-microbial’ interactive effects on genes such as complement cascade components and *nlr3s*, which are orthologs of known inflammatory genes in humans [170].

Leveraging differences in intestinal health evaluated by the number of neutrophils between these same oceanic and freshwater populations, an F2-intercross QTL mapping study identified candidate regions of the stickleback genome associated with increased neutrophil counts [171]. Several associated regions contained orthologs of human genes tied to neurological/neuromuscular syndromes that include secondary gut inflammation symptoms, such as amyotrophic lateral sclerosis, autism spectrum disorder, and muscular dystrophy [172–179]. This finding is significant because some neurological and neuromuscular diseases can be successfully slowed using microbial interventions [180,181]. Together, these studies suggest potential genetic links between neurological disorders and intestinal inflammation and support further exploration of dietary interventions for neurological diseases. Threespine stickleback therefore provide a needed model to test the impact of genetic variation and intestinal inflammation on systemic health.



Trends in Genetics

Figure 5. Threespine stickleback, models of inflammatory bowel diseases. Threespine stickleback from various populations and intercrosses exhibit pronounced differences in neutrophil activity in the gut. Pictured here are two threespine stickleback gut sections from an F2 intercross stained for neutrophils (black dots). (A) Healthy stickleback gut with neutrophils primarily located outside intestinal villi (arrow). (B) Inflamed stickleback gut with neutrophils congregating inside the villi (box).

Concluding remarks

The discovery, description, and use of fish EMMs have greatly increased in the last 10 years. Further exploration of fish EMMs is needed to advance our understanding of human disease (see [Outstanding questions](#)). High-quality genome assemblies offer new avenues of research to elucidate complex genetic underpinnings of disease, particularly through phylomapping. Importantly, molecular advances, including CRISPR-Cas9 genome editing, have made functional testing of candidate genes easier in outbred EMMs. Attention to areas of fundamental science and searches for new EMMs will inform new directions for the study of human disease in the context of genetic variation, enhance our understanding of complex genetic diseases, and may lead to novel treatments not apparent in current inbred animal models. Still, there are several resources that need to be developed to advance fish EMM research ([Box 4](#)).

Additional challenges lie ahead in advancing the utility of fish EMMs. First, while fish EMMs are used to study multiple organ systems, differences between fish and human anatomy must be considered when applying findings in EMMs to human disease treatments. The ability to compare

Outstanding questions

What other EMMs of human diseases remain undiscovered?

What new technologies can be applied to existing EMMs to expand their utility and elucidate underlying mechanisms of human diseases?

Can extreme environments be mined for novel EMMs to understand GxE interactions?

Can rapid adaptation to anthropogenic stressors in natural populations be leveraged to model diseases tied to current patterns of global change?

Can population level genomic sequencing reveal new background-specific mutations of interest?

Box 4. Resources for aquatic evolutionary mutant models of human diseases

To optimize contributions that fish EMMs can make to understand human health, a number of resources are needed that encompass methodological, informatic, phenotyping, and community needs; several such needs surfaced in a workshop entitled 'Validation of Non-Zebrafish Aquatic Models for Preclinical Research' organized by the Division of Comparative Medicine at NIH.ⁱⁱⁱ

Methodological resource needs:

- Protein localization tools: antibodies that work across a broad range of fish species would help validate, or fail to validate, that proteins in an EMM occupy the same cells and subcellular compartments as they do in humans.
- Precise genome editing tools: methods to replace the sequence in an EMM genome with the orthologous human sequence and CRIMIC-like vectors [196], that work in fish to simultaneously knock-in reporter constructs while knocking out and replacing genes, would provide critical tests of sequences responsible for phenotypes.
- Single cell transcriptome sequencing: widespread and inexpensive access to scRNA-seq methodologies, especially methods that retain spatial information [197] and scRNA-seq atlases of fish development [198] would provide cellular-level resolution of mechanisms underlying EMM phenotypes.

Informatic resource needs:

- Gene nomenclature uniformity: it is essential that true orthologs are identified among EMMs, other model organisms, and humans, a task that is not always straightforward due to the teleost genome duplication and ohnologs gone missing [53,192–195].
- A pan-fish informatics database: a database like ZFIN^{iv}, that curates orthologs, gene expression information, and literature across many fish EMM species and that is linked to the Alliance of Genome Resources^v would greatly improve the connectivity of EMMs with each other and to human genomic medicine.

Phenotyping resource needs:

- A phenotype ontology: the widespread use of a standard ontology for anatomical terms and descriptors for deviation from 'normal', like the one in ZFIN^{vi} would foster accurate interspecies comparisons.
- Fuller phenotype descriptions: researchers often focus solely on the single EMM phenotype that interests them rather than describing full EMM phenotypes. More complete descriptions would call attention of other researchers to phenotypes that may mimic human diseases that the original researcher had not recognized or cannot study.

Community needs:

- Conferences: we encourage broad participation of EMM researchers at meetings such as the semi-annual 'Aquatic Models of Human Disease Conference' sponsored by the NIH Division of Comparative Medicine^{vii}.
- Exploration: EMMs often occupy extreme and rare habitats, many of which may disappear as climates change and humans encroach on wild spaces. The community must explore existing biodiversity for EMMs before these remarkable, beautiful, and useful animals become extinct.

across species is further complicated when researchers do not have complete descriptions of molecular processes and systems in an EMM. For example, while fish immunology is a growing field, fundamental questions remain unanswered. The timing of onset of adaptive immunity across fish species varies, with different fish species developing essential components of adaptive immunity at vastly different developmental stages [182]. Fish and mammalian immune systems also differ somewhat in composition, including a lack of fully formed germinal centers in fish, which are important for B cell humoral immune responses. Instead, some fish, including **teleosts**, rely on melanomacrophage centers, which are not found in mammals [183]. Additionally, some fish EMMs are more amenable to large-scale studies than others, depending on whether the species can survive and breed in captivity and the size of the fish (Table 1). In some cases, this limits high-throughput studies to larval or juvenile fish, or to adults from natural populations. Unfortunately, working with smaller organisms can also limit the amount of biological material that can be sampled from individuals, though these are not problems unique to fish EMMs. The lack of biological material can be particularly challenging when working with difficult to obtain samples such as blood, which can be drawn from fish, though this is not a trivial process [184].

Another growing area of significant benefit using fish EMMs is chemical and drug screening, particularly given the high-throughput manner in which thousands of molecules can be screened across thousands of embryos [70,185–187]. Testing toxicity of compounds on large numbers of vertebrate animals can be useful in early screens. Zebrafish have been used in high-throughput screens of ototoxicity, epilepsy, and cancer and have led to the development of FDA-approved drugs, such as leflunomide used to treat arthritis [188], but there are some important considerations that must be accounted for when performing these trials. First, the method of delivery in fish is to submerge fish in the compounds being screened. Full submersion in chemicals is mechanistically very different than how drugs are commonly delivered in mammalian systems; it can prevent tissue-specific treatment and can require large quantities of compound, which can be expensive. Estimating compound solubility is also an important part of drug development: oral ingestion, the most common drug delivery method, may result in different availability to target cells compared with dissolving the same drug in the fish water [189]. Unfortunately, both pharmacokinetic-pharmacodynamic modeling and compound solubility can be difficult in fish due to varying water temperature and salinity conditions impacting drug activity across species [189–191].

Finally, teleost fish researchers must always be aware of the teleost genome duplication event and the phenomenon of ‘**ohnologs** gone missing’: that paralogs from genome duplication events [53,192–195] that occurred before the divergence of tetrapod and teleost lineages were sometimes reciprocally shared between the two lineages, so that for a few genes, neither lineage has an ortholog of the most closely related gene in the other lineage, although their functions are likely to be quite similar.

These potential challenges of using and drawing inferences from models are more than offset by the benefits of the evolutionary diversity of EMMs. Together with traditional model organisms, and powered by the rapid advances in tools, the future is very bright. Expansion of work in fish EMMs will support continued scientific breakthroughs using the vast diversity of models created by nature’s grand laboratory.

Acknowledgments

We would like to thank the editorial staff of Trends in Genetics as well as three anonymous reviewers for helpful comments on this manuscript. This work was supported by the National Institutes of Health grant R01AG031922 from the National Institute on Aging (J.H.P.), the National Institutes of Health Office of the Director grants 5R01OD011116 and R24RR032670 (J.H.P.), the National Institutes of Health grant P50-DA04875602S2 from the National Institute on Drug Abuse (W.A.C.), the National

Institutes of Health grant R24RR032670 from the National Institute of General Medical Sciences (W.A.C), the National Science Foundation grants OPP-1947040 (J.H.P), OPP-1543383 (J.H.P. and T.D.), and OPP-2015301 (W.A.C. and C.M.S), and the National Institute of Health NRSA fellowship F32GM122419 from the National Institute of General Medical Sciences (E.A.B).

Declaration of interests

The authors declare no competing interests.

Resources

ⁱwww.nfed.org/

ⁱⁱ<https://orip.nih.gov/about-orip/workshop-reports>

ⁱⁱⁱhttps://orip.nih.gov/sites/default/files/Validation_Session_VII_Meeting_Report_Final_508.pdf

^{iv}<http://zfin.org/>

^v<https://www.alliancegenome.org/>

^{vi}<https://zfin.org/action/ontology/search>

^{vii}<https://www.mbl.edu/aqmhnd/>

References

- Ko, D.C. *et al.* (2009) A genome-wide in vitro bacterial-infection screen reveals human variation in the host response associated with inflammatory disease. *Am. J. Hum. Genet.* 85, 214–227
- Torkamani, A. *et al.* (2012) Clinical implications of human population differences in genome-wide rates of functional genotypes. *Front. Genet.* 3, 211
- Lu, Y.F. *et al.* (2014) Personalized medicine and human genetic diversity. *Cold Spring Harb. Perspect. Med.* 4, a008581
- Steele, F.R. (2009) Personalized medicine: something old, something new. *Per. Med.* 6, 1–5
- Wangler, M.F. *et al.* (2017) Model organisms facilitate rare disease diagnosis and therapeutic research. *Genetics* 207, 9–27
- Baldrige, D. *et al.* (2021) Model organisms contribute to diagnosis and discovery in the undiagnosed diseases network: current state and a future vision. *Orphanet J. Rare Dis.* 16, 206
- Nüsslein-volhard, C. and Wieschaus, E. (1980) Mutations affecting segment number and polarity in *Drosophila*. *Nature* 287, 795–801
- Landel, C.P. *et al.* (1990) Reverse genetics using transgenic mice. *Annu. Rev. Physiol.* 52, 841–851
- Albertson, R.C. *et al.* (2009) Evolutionary mutant models for human disease. *Trends Genet.* 25, 74–81
- Lescak, E.A. *et al.* (2015) Evolution of stickleback in 50 years on earthquake-uplifted islands. *Proc. Natl. Acad. Sci. U. S. A.* 112, E7204–E7212
- Bell, M. and Foster, S. (1994) Introduction to the biology of the threespine stickleback. In *The Evolutionary Biology of the Threespine Stickleback*, pp. 1–26, Oxford University Press
- Cresko, W.A. *et al.* (2004) Parallel genetic basis for repeated evolution of armor loss in Alaskan threespine stickleback populations. *Proc. Natl. Acad. Sci. U. S. A.* 101, 6050–6055
- Colosimo, P.F. (2005) Widespread parallel evolution in sticklebacks by repeated fixation of ectodysplasin alleles. *Science* 307, 1928–1933
- Kere, J. *et al.* (1996) X-linked anhidrotic (hypohidrotic) ectodermal dysplasia is caused by mutation in a novel transmembrane protein. *Nat. Genet.* 13, 409–416
- Rommens, J.M. *et al.* (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science* 245, 1059–1065
- Ceccaldi, R. *et al.* (2016) The Fanconi anaemia pathway: new players and new functions. *Nat. Rev. Mol. Cell Biol.* 17, 337–349
- Combarros, O. *et al.* (2009) Epistasis in sporadic Alzheimer's disease. *Neurobiol. Aging* 30, 1333–1349
- Peltonen, L. *et al.* (2006) Lessons from studying monogenic disease for common disease. *Hum. Mol. Genet.* 16, R67–R74
- Jackson, M. *et al.* (2018) The genetic basis of disease. *Essays Biochem.* 62, 643–723
- Nagel, R.L. (2005) Epistasis and the genetics of human diseases. *C. R. Biol.* 328, 606–615
- Kikuta, H. *et al.* (2007) Genomic regulatory blocks encompass multiple neighboring genes and maintain conserved synteny in vertebrates. *Genome Res.* 17, 545–555
- Ruzicki, P.A. *et al.* (2015) Graded gene expression changes determine phenotype severity in mouse models of CRX-associated retinopathies. *Genome Biol.* 16, 171
- Smith, M. and Flodman, P.L. (2018) Expanded insights into mechanisms of gene expression and disease related disruptions. *Front. Mol. Biosci.* 5, 101
- Jansson-Knodell, C.L. *et al.* (2020) Lactose intolerance: a concise review to skim the surface. *Mayo Clin. Proc.* 95, 1499–1505
- Williams, T.N. *et al.* (2005) Negative epistasis between the malaria-protective effects of alpha-thalassemia and the sickle cell trait. *Nat. Genet.* 37, 1253–1257
- Schulz, L.O. *et al.* (2006) Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. *Diabetes Care* 29, 1866–1871
- Tang, L. (2020) Disease heritability explained by eQTLs. *Nat. Methods* 17, 655
- Luikart, G. *et al.* (2003) The power and promise of population genomics: from genotyping to genome typing. *Nat. Rev. Genet.* 4, 981–994
- Barreto, M.A. *et al.* (2018) QTL mapping and identification of corresponding genomic regions for black pod disease resistance to three *Phytophthora* species in *Theobroma cacao* L. *Euphytica* 214, 188
- Smith, M.W. and O'Brien, S.J. (2005) Mapping by admixture linkage disequilibrium: advances, limitations and guidelines. *Nat. Rev. Genet.* 6, 623–632
- Hindorf, L.A. *et al.* (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc. Natl. Acad. Sci. U. S. A.* 106, 9362–9367
- Smemo, S. *et al.* (2014) Obesity-associated variants within FTO form long-range functional connections with IRX3. *Nature* 507, 371–375
- Polychronopoulos, D. *et al.* (2017) Conserved non-coding elements: developmental gene regulation meets genome organization. *Nucleic Acids Res.* 45, 12611–12624
- Rahimov, F. *et al.* (2008) Disruption of an AP-2α binding site in an IRF6 enhancer is associated with cleft lip. *Nat. Genet.* 40, 1341–1347
- Emison, E.S. *et al.* (2005) A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease risk. *Nature* 434, 857–863
- Parveen, N. *et al.* (2013) Comparative genomics using teleost fish helps to systematically identify target gene bodies of functionally defined human enhancers. *BMC Genomics* 14, 122

37. Leysen, H. *et al.* (2011) Morphological variation in head shape of pipefishes and seahorses in relation to snout length and developmental growth. *J. Morphol.* 272, 1259–1270
38. Small, C.M. *et al.* (2016) The genome of the Gulf pipefish enables understanding of evolutionary innovations. *Genome Biol.* 17, 258
39. Qiu, M. *et al.* (1997) Role of the Dlx homeobox genes in proximodistal patterning of the branchial arches: mutations of Dlx-1, Dlx-2, and Dlx-1 and -2 alter morphogenesis of proximal skeletal and soft tissue structures derived from the first and second arches. *Dev. Biol.* 185, 165–184
40. Pereira, M.N. *et al.* (2011) Multiple hyperdontia: report of an unusual case. *Am. J. Orthod. Dentofac. Orthop.* 140, 580–584
41. Cleves, P.A. *et al.* (2014) Evolved tooth gain in sticklebacks is associated with a cis-regulatory allele of Bmp6. *Proc. Natl. Acad. Sci. U. S. A.* 111, 13912–13917
42. Stepaniak, M.D. *et al.* (2021) Evolved Bmp6 enhancer alleles drive spatial shifts in gene expression during tooth development in sticklebacks. *bioRxiv* Published online May 16, 2021. <https://doi.org/10.1101/2021.05.14.444181>
43. Daane, J.M. *et al.* (2016) Parallelism and epistasis in skeletal evolution identified through use of phylogenomic mapping strategies. *Mol. Biol. Evol.* 33, 162–173
44. Peichel, C.L. and Marques, D.A. (2017) The genetic and molecular architecture of phenotypic diversity in sticklebacks. *Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci.* 372, 20150486
45. Koshida-Takeuchi, K. *et al.* (2009) Reptilian heart development and the molecular basis of cardiac chamber evolution. *Nature* 461, 95–98
46. Pichon, A. *et al.* (2013) Cardiac adaptation to high altitude in the plateau pika (*Ochotona curzoniae*). *Physiol. Rep.* 1, e00032
47. Liu, C. *et al.* (2021) A towering genome: experimentally validated adaptations to high blood pressure and extreme stature in the giraffe. *Sci. Adv.* 7, eabe9459
48. Stegmann, U.E. (2021) Medical toolkit organisms and Covid-19. *Hist Philos Life Sci* 43, 14
49. Postlethwait, J. *et al.* (2004) Subfunction partitioning, the teleost radiation and the annotation of the human genome. *Trends Genet.* 20, 481–490
50. Santini, F. *et al.* (2009) Did genome duplication drive the origin of teleosts? A comparative study of diversification in ray-finned fishes. *BMC Evol. Biol.* 9, 194
51. Chen, Z. *et al.* (2019) De novo assembly of the goldfish (*Carassius auratus*) genome and the evolution of genes after whole-genome duplication. *Sci. Adv.* 5, eaav0547
52. Glasauer, S.M.K. and Neuhauss, S.C.F. (2014) Whole-genome duplication in teleost fishes and its evolutionary consequences. *Mol. Gen. Genomics* 289, 1045–1060
53. Amores, A. *et al.* (1998) Zebrafish hox clusters and vertebrate genome evolution. *Science* 282, 1711–1714
54. Near, T.J. *et al.* (2012) Resolution of ray-finned fish phylogeny and timing of diversification. *Proc. Natl. Acad. Sci. U. S. A.* 109, 13698–13703
55. van de Peer, Y. *et al.* (2009) The evolutionary significance of ancient genome duplications. *Nat. Rev. Genet.* 10, 725–732
56. Ohno, S. (1971) *Evolution by Gene Duplication*, Springer-Verlag
57. Force, A. *et al.* (1999) Preservation of duplicate genes by complementary, degenerative mutations. *Genetics* 151, 1531–1545
58. Ravi, V. and Venkatesh, B. (2018) The divergent genomes of teleosts. *Annu. Rev. Anim. Biosci.* 6, 47–68
59. Howe, K. *et al.* (2013) The zebrafish reference genome sequence and its relationship to the human genome. *Nature* 496, 498–503
60. Ko, J.M. and Fisher, D.E. (2011) A new era: melanoma genetics and therapeutics. *J. Pathol.* 223, 241–250
61. Gray-Schopfer, V. *et al.* (2007) Melanoma biology and new targeted therapy. *Nature* 445, 851–857
62. Fernandez, A.A. and Morris, M.R. (2008) Mate choice for more melanin as a mechanism to maintain a functional oncogene. *Proc. Natl. Acad. Sci. U. S. A.* 105, 13503–13507
63. Fernandez, A.A. and Bowser, P.R. (2010) Selection for a dominant oncogene and large male size as a risk factor for melanoma in the *Xiphophorus* animal model. *Mol. Ecol.* 19, 3114–3123
64. Sarasamma, S. *et al.* (2018) The power of fish models to elucidate skin cancer pathogenesis and impact the discovery of new therapeutic opportunities. *Int. J. Mol. Sci.* 19, 3929
65. Gordon, M. (1927) The genetics of a viviparous top-minnow *Platyopocilus*; the inheritance of two kinds of melanophores. *Genetics* 12, 253–283
66. Wittbrodt, J. *et al.* (1989) Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in *Xiphophorus*. *Nature* 341, 415–421
67. Scharlt, A. *et al.* (1994) Evolutionary origin and molecular biology of the melanoma-inducing oncogene of *Xiphophorus*. *Pigment Cell Res.* 7, 428–432
68. Scharlt, M. *et al.* (2013) The genome of the platyfish, *Xiphophorus maculatus*, provides insights into evolutionary adaptation and several complex traits. *Nat. Genet.* 567–572
69. Meierjohann, S. and Scharlt, M. (2006) From Mendelian to molecular genetics: the *Xiphophorus* melanoma model. *Trends Genet.* 22, 654–661
70. Lu, Y. *et al.* (2019) Application of the transcriptional disease signature (TDSs) to screen melanoma-effective compounds in a small fish model. *Sci. Rep.* 9, 530
71. Todaro, G.J. and Huebner, R.J. (1972) N.A.S. symposium: new evidence as the basis for increased efforts in cancer research. *Proc. Natl. Acad. Sci. U. S. A.* 69, 1009–1015
72. Wellbrock, C. and Scharlt, M. (1999) Multiple binding sites in the growth factor receptor Xmrk mediate binding to p59(fyn), GRB2 and Shc. *Eur. J. Biochem.* 260, 275–283
73. Wellbrock, C. *et al.* (2005) STAT5 contributes to interferon resistance of melanoma cells. *Curr. Biol.* 15, 1629–1639
74. Packer, L. (2006) Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. *Carcinogenesis* 27, 1778–1786
75. Geissinger, E. *et al.* (2002) Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. *Cancer Res.* 62, 4820–4828
76. Lu, Y. *et al.* (2020) Oncogenic allelic interaction in *Xiphophorus* highlights hybrid incompatibility. *Proc. Natl. Acad. Sci. U. S. A.* 117, 29786–29794
77. Williams, J.A. *et al.* (2009) Small G proteins as key regulators of pancreatic digestive enzyme secretion. *Am. J. Physiol. Endocrinol. Metab.* 296, E405–E414
78. Yang, J. *et al.* (2015) High expression of small GTPase Rab3D promotes cancer progression and metastasis. *Oncotarget* 6, 11125–11138
79. Brady, C.A. *et al.* (2016) Chemical screening in zebrafish. *Methods Mol. Biol.* 1451, 3–16
80. Kim, Y. *et al.* (2016) The short-lived African turquoise killifish: an emerging experimental model for ageing. *Dis. Model. Mech.* 9, 115–129
81. Harel, I. *et al.* (2015) A platform for rapid exploration of aging and diseases in a naturally short-lived vertebrate. *Cell* 160, 1013–1026
82. Seim, I. *et al.* (2013) Genome analysis reveals insights into physiology and longevity of the Brandt's bat *Myotis brandtii*. *Nat. Commun.* 4, 2212
83. Kim, E.B. *et al.* (2011) Genome sequencing reveals insights into physiology and longevity of the naked mole rat. *Nature* 479, 223–227
84. Keane, M. *et al.* (2015) Insights into the evolution of longevity from the bowhead whale genome. *Cell Rep.* 10, 112–122
85. Valenzano, D.R. *et al.* (2015) The African turquoise killifish genome provides insights into evolution and genetic architecture of lifespan. *Cell* 163, 1539–1554
86. Genade, T. *et al.* (2005) Annual fishes of the genus *Nothobranchius* as a model system for aging research. *Aging Cell* 4, 223–233
87. Cui, R. *et al.* (2020) *Nothobranchius furzeri* (African turquoise killifish). *Trends Genet.* 36, 540–541
88. Ballev, B.J. *et al.* (2013) Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in *Dyskeratosis congenita*. *Hum. Genet.* 132, 473–480
89. Eriksson, M. *et al.* (2003) Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome. *Nature* 423, 293–298

90. Smith, P. *et al.* (2017) Regulation of life span by the gut microbiota in the short-lived African turquoise killifish. *Elife* 6, e27014
91. Geister, K.A. and Camper, S.A. (2015) Advances in skeletal dysplasia genetics. *Annu. Rev. Genomics Hum. Genet.* 16, 199–227
92. van Dijk, F.S. and Silencio, D.O. (2014) Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. *Am. J. Med. Genet. A* 164A, 1470–1481
93. Marini, J.C. *et al.* (2017) Osteogenesis imperfecta. *Nat. Rev. Dis. Primers* 3, 17052
94. Near, T.J. *et al.* (2012) Ancient climate change, antifreeze, and the evolutionary diversification of Antarctic fishes. *Proc. Natl. Acad. Sci. U. S. A.* 109, 3434–3439
95. Lenky, C. *et al.* (2012) Proximate composition and energy density of nototheniid and myctophid fish in McMurdo Sound and the Ross Sea, Antarctica. *Polar Biol.* 35, 717–724
96. Eastman, J.T. *et al.* (2014) Divergence in skeletal mass and bone morphology in Antarctic nototheniid fishes. *J. Morphol.* 245, 841–861
97. Scharl, M. (2014) Beyond the zebrafish: diverse fish species for modeling human disease. *Dis. Model. Mech.* 7, 181–192
98. Iwami, T. (1985) Osteology and relationships of the family Channichthyidae. *Mem. Natl. Inst. Polar Res.* 36, 1–69
99. Voskoboinikova, O.S. (2001) Evolutionary significance of heterochronies in the development of the bony skeleton in fishes of the suborder Notothenioidae (Perciformes). *J. Ichthyol.* 41, 415–424
100. Voskoboinikova, O. *et al.* (2017) Evolution reshaped life for the water column: the skeleton of the Antarctic silverfish *Pleuragramma antarctica* Boulenger, 1902. In *The Antarctic Silverfish: A Keystone Species in a Changing Ecosystem* (Vacchi, M. *et al.*, eds), pp. 3–26, Springer
101. Daane, J.M. *et al.* (2019) Historical contingency shapes adaptive radiation in Antarctic fishes. *Nat. Ecol. Evol.* 3, 1102–1109
102. Gistelink, C. *et al.* (2018) Zebrafish type I collagen mutants faithfully recapitulate human type I collagenopathies. *Proc. Natl. Acad. Sci. U. S. A.* 115, E8037–E8046
103. Albertson, R.C. *et al.* (2010) Molecular pedomorphism underlies craniofacial skeletal evolution in Antarctic nototheniid fishes. *BMC Evol. Biol.* 6, 4
104. Canalis, E. and Zanotti, S. (2014) Hajdu-Cheney syndrome: a review. *Orphanet J. Rare Dis.* 9, 200
105. Zuniga, E. *et al.* (2010) Jagged-Notch signaling ensures dorsal skeletal identity in the vertebrate face. *Development* 137, 1843–1852
106. Rotlant, J. *et al.* (2008) Sparc (Osteonectin) functions in morphogenesis of the pharyngeal skeleton and inner ear. *Matrix Biol.* 27, 561–572
107. Kassebaum, N.J. *et al.* (2016) The global burden of anemia. *Hematol. Oncol. Clin. North Am.* 30, 247–308
108. Grove, T.J. *et al.* (2004) Two species of Antarctic icefishes (genus *Champscephalus*) share a common genetic lesion leading to the loss of myoglobin expression. *Polar Biol.* 27, 579–585
109. Høileten, G.F. (1970) Oxygen uptake and circulation by a hemoglobinless Antarctic fish (*Chionocephalus aceratus* Lonnberg) compared with three red-blooded Antarctic fish. *Comp. Biochem. Physiol.* 34, 457–471
110. Spillman, J. and Hureau, J.C. (1966) Observations sur les éléments figurés du sang incolore de *Chaenichthys rhinoceratus* Richardson, poisson téléostéen Antarctique (Chaenichthyidae). *Bull. Mus. Natl. Hist. Nat.* 30, 779–783
111. Barber, D.L. *et al.* (1981) The blood cells of the Antarctic icefish *Chionocephalus aceratus* Lonnberg: light and electron microscopic observations. *J. Fish Biol.* 19, 11–28
112. Romano, N. *et al.* (2002) Cytology of lymphomyeloid head kidney of Antarctic fishes *Trematomus bernacchii* (Nototheniidae) and *Chionodraco hamatus* (Channichthyidae). *Tissue Cell* 34, 63–72
113. Kim, B.M. *et al.* (2019) Antarctic blackfin icefish genome reveals adaptations to extreme environments. *Nat. Ecol. Evol.* 3, 469–478
114. Bargelloni, L. *et al.* (2019) Draft genome assembly and transcriptome data of the icefish *Chionodraco myersi* reveal the key role of mitochondria for a life without hemoglobin at sub-zero temperatures. *Commun. Biol.* 2, 443
115. Near, T.J. *et al.* (2006) A genomic fossil reveals key steps in hemoglobin loss by the Antarctic icefishes. *Mol. Biol. Evol.* 23, 2008–2016
116. Yergeau, D.A. *et al.* (2005) Bloodthirsty, an RBCC/TRIM gene required for erythropoiesis in zebrafish. *Dev. Biol.* 283, 97–112
117. Scudiero, R. *et al.* (2007) Structure and expression of genes involved in transport and storage of iron in red-blooded and hemoglobin-less Antarctic notothenioids. *Gene* 397, 1–11
118. Xu, Q. *et al.* (2015) Evolutionary suppression of erythropoiesis via the modulation of TGF- β signalling in an Antarctic icefish. *Mol. Ecol.* 24, 4664–4678
119. Desvignes, T. *et al.* (2016) Genomic conservation of erythropoietic microRNAs (erythromiRs) in white-blooded Antarctic icefish. *Mar. Genomics* 30, 27–34
120. Bilyk, K.T. *et al.* (2019) A tale of two genes: divergent evolutionary fate of haptoglobin and hemopexin in hemoglobinless Antarctic icefishes. *J. Exp. Biol.* 222, jeb188573
121. Daane, J.M. *et al.* (2020) Developmental constraint shaped genome evolution and erythrocyte loss in Antarctic fishes following paleoclimate change. *PLoS Genet.* 16, e1009173
122. Damsgaard, C. *et al.* (2019) Retinal oxygen supply shaped the functional evolution of the vertebrate eye. *Elife* 8, e52153
123. Lauridsen, H. *et al.* (2019) PO2 profiles in the retina of the hemoglobin-less icefishes. *FASEB J.* 33, lb413
124. Joyce, W. *et al.* (2018) Exploring nature's natural knockouts: in vivo cardiorespiratory performance of Antarctic fishes during acute warming. *J. Exp. Biol.* 221, jeb183160
125. Joyce, W. *et al.* (2019) Adrenergic and adenosinergic regulation of the cardiovascular system in an Antarctic icefish: insight into central and peripheral determinants of cardiac output. *Comp. Biochem. Physiol. A. Mol. Integr. Physiol.* 230, 28–38
126. Egginton, S. *et al.* (2019) Maximum cardiac performance of Antarctic fishes that lack haemoglobin and myoglobin: exploring the effect of warming on nature's natural knockouts. *Conserv. Physiol.* 7, coz049
127. Biederman, A.M. *et al.* (2019) Mitochondrial membranes in cardiac muscle from Antarctic nototheniid fishes vary in phospholipid composition and membrane fluidity. *Comp. Biochem. Physiol. B Biochem. Mol. Biol.* 235, 46–53
128. Harter, T.S. *et al.* (2018) A solution to nature's haemoglobin knockout: a plasma accessible carbonic anhydrase catalyses CO₂ excretion in Antarctic icefish gills. *J. Exp. Biol.* 221, jeb190918
129. Kim, J.B. (2014) Channelopathies. *Korean J. Pediatr.* 57, 1–18
130. Köhling, R. and Wolfart, J. (2016) Potassium channels in epilepsy. *Cold Spring Harb. Perspect. Med.* 6, a022871
131. Zakon, H.H. *et al.* (2006) Sodium channel genes and the evolution of diversity in communication signals of electric fishes: convergent molecular evolution. *Proc. Natl. Acad. Sci. U. S. A.* 103, 3675–3680
132. Bass, A.H. (1986) A hormone-sensitive communication system in an electric fish. *J. Neurobiol.* 17, 131–155
133. Thompson, A. *et al.* (2018) Rapid evolution of a voltage-gated sodium channel gene in a lineage of electric fish leads to a persistent sodium current. *PLoS Biol.* 16, e2004892
134. Gallant, J.R. *et al.* (2014) Genomic basis for the convergent evolution of electric organs. *Science* 344, 1522–1525
135. Arnegard, M.E. *et al.* (2010) Old gene duplication facilitates origin and diversification of an innovative communication system - twice. *Proc. Natl. Acad. Sci. U. S. A.* 107, 22172–22177
136. Lerche, H. *et al.* (1993) Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III-IV linker. *J. Physiol.* 470, 13–22
137. Constantinou, S.J. *et al.* (2019) Silencing the spark: CRISPR/Cas9 genome editing in weakly electric fish. *J. Vis. Exp.* 152
138. Bardien-Kruger, S. *et al.* (2002) Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as

- cause of progressive familial heart block I (PFHBI). *Eur. J. Hum. Genet.* 10, 36–43
139. Swapna, I. *et al.* (2018) Electrostatic tuning of a potassium channel in electric fish. *Curr. Biol.* 28, 2094–2102
 140. James, S.L. *et al.* (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 392, 1789–1858
 141. Via, M.A. and Mechanick, J.I. (2016) Nutrition in type 2 diabetes and the metabolic syndrome. *Med. Clin. North Am.* 100, 1285–1302
 142. Bhupathiraju, S.N. and Hu, F.B. (2016) Epidemiology of obesity and diabetes and their cardiovascular complications. *Circ. Res.* 118, 1723–1735
 143. Bradic, M. *et al.* (2012) Gene flow and population structure in the Mexican blind cavefish complex (*Astyanax mexicanus*). *BMC Evol. Biol.* 12, 9
 144. Aspirasa, A.C. *et al.* (2015) Melanocortin 4 receptor mutations contribute to the adaptation of cavefish to nutrient-poor conditions. *Proc. Natl. Acad. Sci. U. S. A.* 112, 9668–9673
 145. Riddle, M.R. *et al.* (2018) Insulin resistance in cavefish as an adaptation to a nutrient-limited environment. *Nature* 555, 647–651
 146. Rohner, N. (2018) Cavefish as an evolutionary mutant model system for human disease. *Dev. Biol.* 441, 355–357
 147. Hegab, Z. (2012) Role of advanced glycation end products in cardiovascular disease. *World J. Cardiol.* 4, 90–102
 148. Milne, R. and Brownstein, S. (2013) Advanced glycation end products and diabetic retinopathy. *Amino Acids* 44, 1397–1407
 149. Jimenez, V. *et al.* (2018) FGF21 gene therapy as treatment for obesity and insulin resistance. *EMBO Mol. Med.* 10, e8791
 150. Price, E.L. *et al.* (2019) Model organisms at the heart of regeneration. *Dis. Model. Mech.* 12, dmm040691
 151. Stockdale, W.T. *et al.* (2018) Heart regeneration in the Mexican cavefish. *Cell Rep.* 25, 1997–2007
 152. Tang, J.L.Y. *et al.* (2018) The developmental origin of heart size and shape differences in *Astyanax mexicanus* populations. *Dev. Biol.* 441, 272–284
 153. Peuß, R. *et al.* (2020) Adaptation to low parasite abundance affects immune investment and immunopathological responses of cavefish. *Nat. Ecol. Evol.* 4, 1416–1430
 154. Mishra, P. and Chan, D.C. (2014) Mitochondrial dynamics and inheritance during cell division, development and disease. *Nat. Rev. Mol. Cell Biol.* 15, 634–646
 155. Wolff, J.N. *et al.* (2014) Mitonuclear interactions: evolutionary consequences over multiple biological scales. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* 369, 20130443
 156. Burton, R.S. and Barreto, F.S. (2012) A disproportionate role for mtDNA in Dobzhansky-Muller incompatibilities? *Mol. Ecol.* 21, 4942–4957
 157. Niyazov, D.M. *et al.* (2016) Primary mitochondrial disease and secondary mitochondrial dysfunction: importance of distinction for diagnosis and treatment. *Mol. Syndromol.* 7, 122–137
 158. Wallace, D.C. (2015) Mitochondrial DNA variation in human radiation and disease. *Cell* 163, 33–38
 159. Baris, T.Z. *et al.* (2017) Evolved genetic and phenotypic differences due to mitochondrial-nuclear interactions. *PLoS Genet.* 13, e1006517
 160. Rand, D.M. (2017) Fishing for adaptive epistasis using mitonuclear interactions. *PLoS Genet.* 13, e1006662
 161. Flight, P.A. *et al.* (2011) The effects of mitochondrial genotype on hypoxic survival and gene expression in a hybrid population of the killifish, *Fundulus heteroclitus*. *Mol. Ecol.* 20, 4503–4520
 162. Wanders, L.K. *et al.* (2014) Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. *Clin. Gastroenterol. Hepatol.* 12, 756–764
 163. Stidham, R.W. and Higgins, P.D.R. (2018) Colorectal cancer in inflammatory bowel disease. *Clin. Colon Rectal Surg.* 31, 168–178
 164. Kumar, M. *et al.* (2019) Integrating omics for a better understanding of inflammatory bowel disease: a step towards personalized medicine. *J. Transl. Med.* 17, 419
 165. Hohenlohe, P.A. *et al.* (2010) Population genomics of parallel adaptation in threespine stickleback using sequenced RAD tags. *PLoS Genet.* 6, e1000862
 166. Small, C.M. *et al.* (2019) Highly reproducible 16S sequencing facilitates measurement of host genetic influences on the stickleback gut microbiome. *mSystems* 4, e00331-19
 167. Rennison, D.J. *et al.* (2019) Parallel changes in gut microbiome composition and function during colonization, local adaptation and ecological speciation. *Proc. Biol. Sci.* 286, 20191911
 168. Goodrich, J.K. *et al.* (2016) Cross-species comparisons of host genetic associations with the microbiome. *Science* 352, 532–535
 169. Milligan-Mhyre, K. *et al.* (2016) Innate immune responses to gut microbiota differ between oceanic and freshwater threespine stickleback populations. *Dis. Model. Mech.* 9, 187–198
 170. Small, C.M. *et al.* (2017) Host genotype and microbiota contribute asymmetrically to transcriptional variation in the threespine stickleback gut. *Genome Biol. Evol.* 9, 504–520
 171. Beck, E.A. *et al.* (2020) QTL mapping of intestinal neutrophil variation in threespine stickleback reveals possible gene targets connecting intestinal inflammation and systemic health. *G3 (Bethesda)* 10, 613–622
 172. Wright, M.L. *et al.* (2018) Potential role of the gut microbiome in ALS: a systematic review. *Biol. Res. Nurs.* 20, 513–521
 173. Patusco, R. and Ziegler, J. (2018) Role of probiotics in managing gastrointestinal dysfunction in children with autism spectrum disorder: an update for practitioners. *Adv. Nutr.* 9, 637–650
 174. Spielman, L.J. *et al.* (2018) Unhealthy gut, unhealthy brain: the role of the intestinal microbiota in neurodegenerative diseases. *Neurochem. Int.* 120, 149–163
 175. Rowin, J. *et al.* (2017) Gut inflammation and dysbiosis in human motor neuron disease. *Physiol. Rep.* 5, e13443
 176. Hughes, H.K. *et al.* (2018) The gut microbiota and dysbiosis in autism spectrum disorders. *Curr. Neurol. Neurosci. Rep.* 18, 81
 177. Lo Cascio, C.M. *et al.* (2016) Gastrointestinal dysfunction in patients with Duchenne muscular dystrophy. *PLoS One* 11, e1063779
 178. Fang, X. (2016) Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis. *Int. J. Neurosci.* 126, 771–776
 179. Bellini, M. (2006) Gastrointestinal manifestations in myotonic muscular dystrophy. *World J. Gastroenterol.* 12, 1821–1828
 180. Huang, H. *et al.* (2019) Fecal microbiota transplantation to treat Parkinson's disease with constipation: a case report. *Medicine (Baltimore)* 98, e16163
 181. Kang, D.-W. *et al.* (2017) Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. *Microbiome* 5, 10
 182. Seemann, F. *et al.* (2017) The development of cellular immune defence in marine medaka *Oryzias melastigma*. *Comp. Biochem. Physiol. C Toxicol. Pharmacol.* 199, 81–89
 183. Steinel, N.C. and Bolnick, D.I. (2017) Melanomacrophage centers as a histological indicator of immune function in fish and other poikilotherms. *Front. Immunol.* 8, 827
 184. Lawrence, M.J. *et al.* (2020) Best practices for non-lethal blood sampling of fish via the caudal vasculature. *J. Fish Biol.* 97, 4–15
 185. Gehrig, J. *et al.* (2018) Zebrafish as a model for drug screening in genetic kidney diseases. *Front. Pediatr.* 6, 183
 186. Miller, J.L. *et al.* (2009) Selection and application of a rainbow trout toxicity testing procedure for screening Sacramento River Watershed, California samples. *Environ. Monit. Assess.* 150, 1–4
 187. Klotz, B. *et al.* (2018) Expression signatures of early-stage and advanced medaka melanomas. *Comp. Biochem. Physiol. C Toxicol. Pharmacol.* 208, 20–28
 188. Phillips, J.B. and Westerfield, M. (2014) Zebrafish models in translational research: tipping the scales toward advancements in human health. *Dis. Model. Mech.* 7, 739–743
 189. Savjani, K.T. *et al.* (2012) Drug solubility: importance and enhancement techniques. *ISRN Pharm.* 2012, 195727
 190. Rigos, G. and Smith, P. (2015) A critical approach on pharmacokinetics, pharmacodynamics, dose optimisation and

- withdrawal times of oxytetracycline in aquaculture. *Rev. Aquacult.* 7, 77–106
191. Rairat, T. *et al.* (2019) Pharmacokinetic–pharmacodynamic modelling for the determination of optimal dosing regimen of florfenicol in Nile tilapia (*Oreochromis niloticus*) at different water temperatures and antimicrobial susceptibility levels. *J. Fish Dis.* 42, 1181–1190
 192. Taylor, J.S. (2003) Genome duplication, a trait shared by 22,000 species of ray-finned fish. *Genome Res.* 13, 382–390
 193. Postlethwait, J.H. (2007) The zebrafish genome in context: ohnologs gone missing. *J. Exp. Zool. B Mol. Dev. Evol.* 308, 563–577
 194. Postlethwait, J. *et al.* (1999) The zebrafish genome. *Methods Cell Biol.* 60, 149–163
 195. Jaillon, O. *et al.* (2004) Genome duplication in the teleost fish *Tetraodon nigroviridis* reveals the early vertebrate proto-karyotype. *Nature* 431, 946–957
 196. Kanca, O. *et al.* (2019) An efficient CRISPR-based strategy to insert small and large fragments of DNA using short homology arms. *Elife* 8, e51539
 197. Hunter, M.v. *et al.* (2020) Spatial transcriptomics reveals the architecture of the tumor/microenvironment interface. *bioRxiv* Published online November 5, 2020. <https://doi.org/10.1101/2020.11.05.368753>
 198. Farnsworth, D.R. *et al.* (2021) Single cell transcriptomics of the developing zebrafish lens and identification of putative controllers of lens development. *Exp. Eye Res.* 206, 108535
 199. Traeger, L.L. *et al.* (2015) Unique patterns of transcript and miRNA expression in the South American strong voltage electric eel (*Electrophorus electricus*). *BMC Genomics* 16, 243
 200. McGaugh, S.E. *et al.* (2014) The cavefish genome reveals candidate genes for eye loss. *Nat. Commun.* 5, 5307
 201. Reid, N.M. *et al.* (2016) The genomic landscape of rapid repeated evolutionary adaptation to toxic pollution in wild fish. *Science* 354, 1305–1308
 202. Jones, F.C. *et al.* (2012) The genomic basis of adaptive evolution in threespine sticklebacks. *Nature* 484, 55–61
 203. Rabosky, D.L. *et al.* (2018) An inverse latitudinal gradient in speciation rate for marine fishes. *Nature* 559, 392–395